Cargando…

Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer

Cancer treatment is being revolutionized by the emergence of immunotherapies such as immune checkpoint inhibitors and therapeutic cancer vaccines. Prostate cancer is amenable to such therapeutic approaches. The improved understanding of the relationship between the immune system and tumors has allow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burotto, Mauricio, Singh, Nishith, Heery, Christopher R., Gulley, James L., Madan, Ravi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264488/ https://www.ncbi.nlm.nih.gov/pubmed/25566495 http://dx.doi.org/10.3389/fonc.2014.00351

Ejemplares similares

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Developing immunotherapy strategies in the treatment of prostate cancer
por: Gulley, James L., et al.
Publicado: (2016)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

MAP4K4 and cancer: ready for the main stage?
por: González-Montero, Jaime, et al.
Publicado: (2023)

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer
por: Kwilas, Anna R., et al.
Publicado: (2012)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Adjuvant therapy for renal cell carcinoma, finally a new standard?
por: Renner, Alex, et al.
Publicado: (2022)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Exploiting the synergy between great and small
Publicado: (2005)

Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
por: Kim, Joseph W., et al.
Publicado: (2012)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma
por: De Martino, Mara, et al.
Publicado: (2021)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches
por: van de Donk, Niels W. C. J., et al.
Publicado: (2020)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Exploiting the Synergy between Carboplatin and ABT-737 in the Treatment of Ovarian Carcinomas
por: Jain, Harsh Vardhan, et al.
Publicado: (2014)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

Postural Hand Synergies during Environmental Constraint Exploitation
por: Della Santina, Cosimo, et al.
Publicado: (2017)

Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
por: Casey, Dana L., et al.
Publicado: (2019)

Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
por: Christopoulos, Petros, et al.
Publicado: (2023)

En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer
por: Yang, Yongjun, et al.
Publicado: (2021)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma
por: Burotto, Mauricio, et al.
Publicado: (2017)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Exploiting synergies between microbial electrochemical technologies and synthetic biology
por: Lai, Bin, et al.
Publicado: (2023)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Comparison of treatment plans for hypofractionated high‐dose prostate cancer radiotherapy using the Varian Halcyon and the Elekta Synergy platforms
por: Tamihardja, Jörg, et al.
Publicado: (2021)

Revisiting the Tenascins: Exploitable as Cancer Targets?
por: Tucker, Richard P., et al.
Publicado: (2022)

Optimizing the synergy between stereotactic radiosurgery and immunotherapy for brain metastases
por: Yoo, Kelly H., et al.
Publicado: (2023)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

MRI and Targeted Biopsy Essential Tools for an Accurate Diagnosis and Treatment Decision Making in Prostate Cancer
por: Samtani, Suraj, et al.
Publicado: (2021)

Primary Adrenal Insufficiency during Immune Checkpoint Inhibitor Treatment: Case Reports and Review of the Literature
por: Salinas, Carlos, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?
por: Renner, Alex, et al.
Publicado: (2019)

Immune Infiltration and Prostate Cancer
por: Strasner, Amy, et al.
Publicado: (2015)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5r08n8ajnrunsqeeads59p48np